Impact of Uterine Adenomyosis on Survival Outcome of Patients with Non-Endometrioid Endometrial Cancer

Levent Özgen, Yakup Yalçın, Merve Abay, Kemal Özerkan
In: Research Square · 2024 · doi:10.21203/rs.3.rs-4803752/v1 · W4401971251
preprint OA: green CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This study compared survival outcomes in non-endometrioid endometrial cancer patients with and without adenomyosis, finding no significant difference in disease-free survival but a higher overall survival in the presence of adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This retrospective single-center study examined 139 patients with surgically treated non-endometrioid endometrial cancer (1998–2023) to compare overall survival and disease-free survival between those with histologically proven uterine adenomyosis (n=40) and those without (n=99). Using hospital records and pathology review, the authors reported that the two groups did not differ significantly in demographic characteristics or major pathological variables, and Kaplan–Meier analysis showed no significant differences in recurrence time, disease-free survival, or cancer-related death rates. In contrast, overall survival was significantly higher in patients with adenomyosis (172±24.1 months) versus those without (102±13.9 months; p=0.02). The paper does not state a specific limitation beyond exclusions for insufficient data, but as a retrospective cohort it remains subject to missingness/selection effects. This paper is centrally about adenomyosis in endometrial cancer — specifically its association with survival in non-endometrioid endometrial cancer.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (15)

Source provenance

europepmc
last seen: 2026-06-11T06:38:44.028908+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK